Oral cyclophosphamide and prednisone are standard treat ment for some neoplasms and necrotizing systemic vasculitis and are advocated with increasing frequency for idiopathic interstitial lung disease. During a 15-month period, we observed four cases of acute respiratory failure from Pnetimocystis carinii pneumonia (PCP) in patients treated with oral cyclophosphamide and prednisone. One patient each had polyarteritis nodosa, Wegener's granulomatosis, bronchiolitis obliterans with organizing pneumonia, and chronic lymphocytic leukemia with red blood cell aplasia. Hypoalbuminemia (serum albumin level <3.0 g/dl) and daily therapy were associated with increased risk for development of PCP (p<0.05). None of the patients had leukopenia (<3,500/cu mm) or neutropenia (<l,000/cumm) at diagnosis. All were negative for the human immunodefi ciency virus. Patients receiving oral cyclophosphamide and prednisone may be at higher or increasing risk for PCP. Â¥Tntil recently, patients afflicted with certain malignant neoplasms and aggressive nonneoplastic conditions (eg, necrotizing systemic vasculitis, inter stitial lung disease) had a poor prognosis and few therapeutic options. For example, patients with Wege ner's granulomatosis had a mean survival of five months, and those with idiopathic pulmonary fihrosis (IFF) had a three-to four-year survival. Fauci and colleagues1"1' presented a series of articles documenting improved survival with polyarteritis nodosa, lymphomatoid grannlomatosis, and Wegener's granulomatosis using combination therapy with eyclophoshamide and prednisone. Gadek and Allen4 extrapolated from the experience of Turner-Warwick and Haslam5 to rec ommend combination therapy for some patients with IFF. Investigators reported few instances of serious or life-threatening toxicity, with primary concerns about hemorrhagic cystitis or development of second malig nancies,1 although recent reports document fatal in fections and a variety of neoplasms associated with cytotoxic therapy."7 During a 15-month period, we have observed four episodes of acute respiratory failure in patients receiving daily cyclophosphamide and prednisone. During the same period, nine patients received similar therapy without major complications.
Â¥Tntil recently, patients afflicted with certain malignant neoplasms and aggressive nonneoplastic conditions (eg, necrotizing systemic vasculitis, inter stitial lung disease) had a poor prognosis and few therapeutic options. For example, patients with Wege ner's granulomatosis had a mean survival of five months, and those with idiopathic pulmonary fihrosis (IFF) had a three-to four-year survival. Fauci and colleagues1"1' presented a series of articles documenting improved survival with polyarteritis nodosa, lymphomatoid grannlomatosis, and Wegener's granulomatosis using combination therapy with eyclophoshamide and prednisone. Gadek and Allen4 extrapolated from the experience of Turner-Warwick and Haslam5 to rec ommend combination therapy for some patients with IFF. Investigators reported few instances of serious or life-threatening toxicity, with primary concerns about hemorrhagic cystitis or development of second malig nancies,1 although recent reports document fatal in fections and a variety of neoplasms associated with
The opinions within are solely those of the authors and do not represent those of the Navy at large, the Department of Defense, or the Naval Medical Department. cytotoxic therapy."7 During a 15-month period, we have observed four episodes of acute respiratory failure in patients receiving daily cyclophosphamide and prednisone. During the same period, nine patients received similar therapy without major complications.
CASEREPORTS CASE1
A 56-year-old woman presented with contusion, sinus congestion, and multiple cavitary pulmonary infiltrates. A nasal biopsy specimen demonstrated necroti/.ing granulomatous inflammation, consistent with Wegeners granulomatosis. She was placed on a regimen of prednisone and cyclophosphamide (150 mg) and had a dramatic clinical response with resolution of her confusion and diminution of her infiltrates. Her rheumatologist was unable to taper her predni sone dose below 20 ing at two months, and dyspnea, hypoxemia, and diffuse pulmonary infiltrates developed. An open lung biopsy specimen showed changes consistent with drug-induced lung dis ease and PnetOHOCyttit carinii cysts, without a characteristic alveolar exudate. Despite ventilatory support and appropriate management, her infiltrates progressed and the patient died. No postmortem examination was done.
CASE2
A 71-year-old man with a malignant thymoma diagnosed in 1981 was treated with radiation therapy. A malignant left pleural effusion developed in 1986 that remained stable with prednisone therapy. His dyspnea progressed in conjunction with the development of diffuse interstitial lung disease. An open lung biopsy specimen in June 1988 demonstrated bronchiolitis obliterans with organizing pneumonia. This failed to respond to 60 mg of prednisone a day after three months, and he was then placed on a regimen of cyclophosphainide (125 mg/day) with 30 mg of prednisone. Two months later, fever and diffuse infiltrates developed and he required mechanical ventilation. A transhronchial lung biopsy specimen demonstrated P rdrinii. Despite improvement with trimethoprim-siillamethoxu/ole. lie remained ventilator dependent lor five months and subsequently died. No |X)Stinortein examination was per formed.
CASES
A fiO-year-old man presented with chronic cough, fever of unknown origin, and iixotemia. A renal biopsy specimen showed necroti/,ing glomcrulitis and (lor presumptive polyarteritis nodosa) the patient was placed on a regimen of cyclophosphamide (1.50 mg) and prednisone (80 mg), which was tapered to 40 mg daily, limited by increasing a/oteiniu. \\'ithin three months, difluse pulmonary infiltrates, fever, and hyi>oxemia requiring mechanical ventilation developed.
Bronchoalveolar lavage showed P curinii pneumonia (POP). Renal failure and progressive lung disease developed in the patient despite trimethoprim-sulfamethoxa/ole and pentamidine therapy, and he died. No postmortem examination was obtained.
CASE4
A 61-year-old man with a six-year history of chronic lymphocytic leukemia (CLL) with splenomegaly and red blood cell aplasia received cyclophosphamide (100 mg) and prednisone (40 mg) for six weeks. Fever, diffuse pulmonary infiltrates, and severe hypoxemia developed. A bronchoalveolar lavage demonstrated P curinii, and treatment with cyclophosphamide was discontinued. On the third hospital day, despite trimethoprim-sulfamethoxa/ole therapy, res piratory failure developed requiring mechanical ventilation. He ultimately recovered.
Data Analysis
A computerized search for all patients receiving oral cyclophos phamide and prednisone during a 15-month period was performed at the National Naval Medical (.'enter pharmacy to establish patient nse of cyclophosphamide and prednisone. We restricted our analysis of cyclophosphamide and prednisone pulmonary toxicity to those patients using outpatient (oral) therapy with these agents. We also reviewed the number ot patients treated with prednisone without cyclophosphamidc who had CLL, bronchiolitis obliterans, or sys temic vasculitis during a similar time period. Statistical comparisons were generated using Student's ( test for parametric statistics and Fisher's exact test for nonp.name-trie statistics. This information is presented in Table 1 . develop, including PCE Three of the nine patients without complications had myeloma, three had nonHodgkins lyniphoma, and one each had breast cancer, Wegeners granulomatosis, and systemic lupus erythematosus. Patients in whom PCP developed had lower serum albumin levels and received daily doses of cyclophosphamide and prednisone. Three of the four patients in whom PCP developed had serum albumin levels less than 3.0 g/dl (30 g/L), while none of the intermittent cyclophosphamide and prednisone group had albumin levels less than 3.0 g/dl (30 g/L) during the survey period (p = 0.018). Three of four patients with acute toxicity had less than 500 lymphocytes per cubic millimeter (by differential cell count), while the fourth had CLL. Relative proportions of lymphocytes were not determined. None of the patients who had development of respiratory failure had a total WBC count of less than 3,000/cu mm or total polymorphonuclear leukocytes of less than 1,500/cu mm. There was no significant difference in the mean age of the two groups. Among patients who had complications develop, cyclophosphamide doses ranged from 100 to 150 mg daily, with prednisone 20 to 40 mg daily at the time of complications. In the group without compli cations, cyclophosphamide was never used for more than five clays per mouth, at a dose of 800 ing/day. Only two of the latter group were receiving "immunosuppressive" therapy, while seven received cancer chemotherapy with imnumosuppression as a second ary effect. Sustained neutropenia was seen in neither group. During the specified time period, all patients who had PCP develop in our institution had either the acquired immunodeficiency syndrome (AIDS) or were receiving oral cyclophosphamide and predni sone. Four of six patients with CLL, systemic vascu litis, or bronchiolitis obliterans receiving oral cyclo phosphamide and prednisone during this period had PCP develop, while none of 32 patients with the same conditions (CLL, 22 patients; bronchiolitis obliterans, five patients; vasculitis, five patients) receiving pred nisone without cyclophoshamide had PCP develop (p=.(MK)2). No patient with PCP in our institution between 1986 and 1990has received prednisone alone.
RESULTS

Four of 13 patients had pulmonary complications
DISCUSSION
Progressive and ultimately fatal conditions such as cancer, necrotizing systemic vasculitis, and IPF justify some of the potential risk associated with immunosuppressive therapy. Cyclophosphamide reduces the cir culating pool of mononuclear phagocytes producing both monocytopenia and lymphopenia.8 Although a total peripheral lymphocyte count of less than 500/cti mm is associated with significant immunosuppression, infection risks are more closely associated with total granulocyte counts.'1 Pnetimocy.stixcarinii pneumonia has emerged as a frequent opportunistic pathogen in immunosuppressed patients, particularly those with AIDS.10 Both cyclophosphamide and prednisone have been implicated as capable of producing immunosuppression contributing to the development of PCP presumably related to T-cell dysfunction." O Donnell and associates12 have shown greater suppression of neutrophil alveolitis in IFF with either cyclophospha mide or cyclophosphamide and prednisone than with prednisone alone. The quantitative effects of cyclo phosphamide and prednisone on pulmonary cellmediated immunity are less clear, although Hughes et al13established that the likelihood of PCP relates to the intensity of immunosuppression.
The contribution of cyclophosphamide and predni sone to impaired cell-mediated immunity is not new information,14 although the frequency of complications varies. Pneumocystis carinii has previously been iden tified as a cause of respiratory morbidity in patients with lymphoma receiving combination chemother apy.15Thirty of 39 patients without AIDS who had PCP develop were receiving both prednisone and cytotoxic therapy.16Three patients died of PCP among 44 fatalities with systemic lupus erythematosus in one series/' Twelve of 53 patients with PCP whose cases were reported by the Mayo Clinic were receiving steroids alone, while four were receiving cytotoxic therapy without steroids.17 However, among 71 pa tients with polyarteritis nodosa and Churg-Strauss angiitis receiving cytotoxic therapy (including cyclo phosphamide and prednisone in 45 patients), no cases of PCP are presented.18 Individual cases of PCP may not be deemed "newsworthy" by physicians using immunosuppression, leading to possible case under reporting. Our experience suggests that PCP is the principal early risk associated with daily oral cyclo phosphamide and prednisone therapy. Cyclophospha mide pulmonary toxicity is an uncommon entity, a diagnosis of exclusion, and represents an idiosyncratic pulmonary reaction characterized by hyperplasia of type 2 pneumocytes.'" Limited use of open lung biopsy and lack of reporting requirements of drug-induced lung disease may result in underdiagnosis and under reporting of pulmonary drug toxicity.20Only one of our four patients developing acute respiratory failure had pulmonary drug toxicity from cyclophosphamide substantiated by open lung biopsy specimen.
The frequency with which pulmonary complications developed in our patients in conjunction with daily cyclophosphamide and prednisone therapy is unique. All patients had respiratory failure develop that re quired mechanical ventilation, and three eventually died. Two of the patients had underlying neoplasms, although neither CLL nor malignant thymoma are ordinarily associated with PCE Our patients with CLL, vasculitis, and bronchiolitis obliterans treated with daily prednisone with or without intermittent alkylating agents have not had PCP develop. We believe this strongly implicates the daily administra tion of cyclophosphamide in the pathogenesis of PCP. Although defective antigen presentation in CLL may account for some defects in cell-mediated immunity (CMI), some defects in CMI are attributed to therapy. 21 The reduced serum albumin level seen in these patients, reflecting diminished visceral protein stores, may have contributed to immunosuppression and development of PCR22
The treatment protocol of Fauci et al1for Wegener's granulomatosis included initiation of cyclophospha mide therapy at an oral dose of 2 mg/kg of body weight, continued for variable periods. Simultane ously, prednisone (1 mg/kg of body weight) was admin istered for two to four weeks until cyclophosphamide effects were noted. The prednisone dosage was then tapered over one to two months to an alternate-day regimen.' Leavitt and Fauci23have more recently noted that by the third month of therapy, "the patient should be maintained on 1 mg/kg of prednisone on alternate days." The duration (but not the doses) of daily cyclophosphamide and preduisone in the patients in whom we diagnosed PCP modestly exceeded Faucis guidelines, because limited clinical responses to ther apy prevented further prednisone tapering. None of the patients had development of PCP coincident with withdrawal of prednisone therapy. It is unknown whether strict adherence to the Fauci protocol would have prevented development of PCP Only one of the patients (Case 1) had been recently hospitalized, making in-hospital acquisition of the agent unlikely. The patients had four different diagnoses and had received care from four different physicians, rendering systematic prescription or follow-up errors unlikely. The finding of severe lymphopenia in three of the four patients is a tantali/.ing explanation to account for the toxicity seen, and none of the four patients had either profound granulocytopeiiia or leukopenia. Severe lym phopenia (T4 cells <2(K)/cu mm) has been associated with increasing frequency of PCP in several studies in patients with AIDS.24-25 Although we cannot fully explain the frequency of PCP with daily cyclophosphamide and prednisone therapy in our institution, we believe our experience provides convincing evidence that the combination of daily doses of cyclophosphamide and preduisone con tributed to development of PCP. We believe the frequency and severity of complications suggests the following recommendations: (1) strong consideration of PCP in any patient receiving daily doses of cyclo phosphamide and prednisone who has development of symptoms or signs of pulmonary infection; (2) consideration of prophylactic trimethoprim-sulfamethoxa/.ole therapy in these patients; and (3) possibly limiting use of daily doses of cyclophosphamide/ prednisone in IFF to patients with histologieally proven disease \vho have not responded to initial prednisone therapy, until further prospective data substantiate a favorable change in the natural history of IFF with initial cytotoxic therapy. Serial monitoring of carbon monoxide diffusing capacity (Deo), which is generally reduced when PCP is diagnosed," could potentially detect subclinical pulmonary function changes. Because the duration of symptoms with PCP associated with immimosnppressive diseases other than AIDS is short,"1 and previous frequency of PCP with cyclophosphamide and prednisone is low, the value of serial Deo determination is uncertain. Eval uation of quantitative measurements of cell-mediated immunity (eg, peripheral helper T cells, bronchoalveolar lavage, delayed hypersensitivity testing) and their correlation with "safe" and effective immunosuppression may establish better guidelines for "appro priate" immunosuppression. Although cyclophosphamide is sometimes considered a means to reduce steroid side effects, it carries a significantly different set of risks, both acute (hemorrhagic cystitis and opportunistic infection) and chronic toxicity (bladder carcinoma and hematologic malignancy), which may be either underreported or increasing in incidence.
